Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $240

Benzinga · 2d ago
Guggenheim analyst Michael Schmidt maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $235 to $240.